Clinical bottom line
Artificial intelligence (AI) and machine learning (ML) models are emerging as promising tools for predicting gastrointestinal bleeding (GIB) risk across diverse patient populations, including those with acute myocardial infarction, pediatric vasculitis, and post-cardiac surgery. These models often outperform traditional risk scores by integrating complex clinical variables and enabling personalized risk stratification. However, challenges remain in ensuring fairness, interpretability, and clinical integration. AI-driven prediction may enhance early identification of high-risk patients, optimize resource allocation, and guide tailored interventions pending further validation and implementation studies (Kou et al., 2025; Dong et al., 2025).
What the evidence shows
Kou et al. (2025) developed a multicenter retrospective cohort model identifying risk factors for GIB in acute myocardial infarction patients. Their AI model demonstrated improved predictive accuracy over conventional scores, highlighting variables such as antithrombotic use and comorbidities.
Dong et al. (2025) applied machine learning to predict GIB after coronary artery bypass grafting, achieving high prognostic performance and enabling personalized medicine approaches by stratifying patients for prophylactic strategies.
Chen et al. (2025) utilized an interpretable transformer model to predict GIB risk in pediatric Henoch-Schönlein purpura, emphasizing the potential for AI in rare and complex pediatric conditions.
Li et al. (2025) addressed fairness gaps in AI risk prediction for GIB, proposing methods to mitigate bias related to demographic and socioeconomic factors, critical for equitable clinical application.
Mahani et al. (2019) compared AI models predicting laboratory value trajectories in ICU patients with GIB, underscoring the impact of comorbidities and medications on model accuracy.
Kumar et al. (2026) explored AI’s role in predicting endotherapy requirements in upper GIB, suggesting that machine learning can assist procedural planning and resource optimization.
Li et al. (2023) compared traditional risk scores for acute lower GIB, providing a benchmark for AI model performance and highlighting areas for improvement.
Caveats and uncertainty
Most AI models are developed retrospectively and require prospective validation.
Heterogeneity in datasets, patient populations, and clinical settings limits generalizability.
Interpretability of complex models remains a barrier to clinician trust and adoption.
Potential biases and fairness issues must be rigorously addressed to avoid health disparities.
Integration into clinical workflows and impact on patient outcomes need further study.
How this may change practice
AI-based risk prediction tools could supplement existing clinical decision-making, enabling earlier identification of patients at high risk for GIB.
Personalized risk stratification may guide prophylactic interventions, monitoring intensity, and resource allocation.
Enhanced prediction of endotherapy needs may improve procedural planning and reduce complications.
Addressing fairness and interpretability will be essential for equitable and effective implementation.
Collaboration between clinicians, data scientists, and informaticians will facilitate translation from research to bedside.